WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Search Results

Now showing 1 - 9 of 9
  • Item
    Staging with PET-CT in Patients with Locally Advanced Non Small Cell Lung Cancer is Superior to Conventional Staging Methods in Terms of Survival
    (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2013-01-01) Mutlu, Hasan; Buyukcelik, Abdullah; Erden, Abdulsamet; Aslan, Tuncay; Akca, Zeki; Kaya, Eser; Kibar, Mustafa; Seyrek, Ertugrul; Yavuz, Sinan; Calikusu, Zuleyha
    Background: Of patients with non small cell lung cancer (NSCLC), around one third are locally advanced at the time of diagnosis. Because only a proprotion of stage III patients can be cured by surgery, in order to improve the outcomes, sequential or concurrent chemoradiation, or concurrent chemoradiation with induction or consolidation is offered to the patients with locally advanced NSCLC. Today, PET combined with computerized tomography (PET-CT) is accepted as the most sensitive technique for detecting mediastinal lymph node and extracranial metastases from NSCLC. We aimed to compare PET-CT and conventional staging procedures for decisions regarding curative treatment of locally advanced NSCLC. Materials and Methods: A total of 168 consecutive patients were included from Acibadem Kayseri Hospital, Acibadem Adana Hospital and Kayseri Research and Training Hospital in this study. Results: While the median PFS was 13.0 +/- 1.9 months in the PET-CT group, it was only 6.0 +/- 0.9 in the others (p<0.001). The median OS values were 20.5 +/- 15.6 and 11.5 +/- 1.5 months, respectively (p<0.001). Discussion: As a result, we found that staging with PET CT has better results in terms of survival staging. This superiority leads to survival advantage in patients with locally advanced NSCLC.
  • Item
    Does Sunlight Exposure Improve Survival in Patients with Non-small Cell Lung Cancer?
    (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2013-01-01) Mutlu, Hasan; Buyukcelik, Abdullah; Aksahin, Arzu; Kibar, Mustafa; Cihan, Yasemin Benderli; Kaya, Eser; Seyrek, Ertugrul; Yavuz, Sinan; Erden, Abdulsamet; Calikusu, Zuleyha; Aslan, Tuncay; Akca, Zeki
    Background: Some epidemiological studies reported that sunlight exposure and highvitamin D levels may decrease the morbidity and mortality related to cancer. We aimed to evaluate whether sunlight exposure has an impact on survival in patients with non small cell lung cancer. Materials and Methods: A total of 546 patients with NSCLC from two different regions (Kayseri and Adana) differing according to sunlight exposure were analysed retrospectively. Results: The median overall survival (OS) rates were 11. 6 (CI: 9.50-13.6) and 15.6 months (CI: 12.4-18.8) for Kayseri and Adana, respectively, in all patients (p=0.880). Conclusions: There were no differences between groups in terms of OS. While there is strong evidence regarding inverse relationship between cancer incidence and sunlight exposure, it is still controversial whether sunlight exposure is a good prognostic factor for survival in patients with lung cancer.
  • Thumbnail Image
    Item
    The Prognostic Significance of Complete Response Rates in Patients with Extensive Stage Small Cell Lung Cancer
    (KARE PUBL, 2019-01-01) Sedef, Ali Murat; Calikusu, Zuleyha; Bahceci, Aykut; Gokcay, Serkan; Sumbul, Ahmet Taner
    OBJECTIVE Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. Platinum-etoposide chemotherapy combination is used as first line treatment. The aim of this trial is evaluate the effect of complete response rates and clinical features in patients with extensive stage (ES) SCLC. METHODS In this retrospective study, a total of 117 patients from four different oncology centers in Turkey between 2011 and 2017 were divided into 2 groups, namely, patients with complete response (group 1) and those with no complete response (group 2) after platin-etoposide combination therapy. RESULTS The median age of the patients was 61 (range 38-81) years. The median follow-up time was 12 months and 95 (81\%) patients died. Progression-free survival (PFS) and overall survival (OS) were estimated, respectively, as 8 and 13 months. Overall survival of group 1 patients was statistically significantly better than the group 2 (16 versus 10 months respectively and p=0.00). The overall survival of patients who had late recurrent disease (>6 mo.) was statistically significantly better than the early ones (<6 mo) (19 versus 14 months respectively and p=0,008). CONCLUSION Complete response and recurrent free time were the prognostic factors for ES SCLC patients in our study
  • Thumbnail Image
    Item
    Prognostic value of basal neutrophil lymphocyte ratio in patients with extensive stage small cell lung cancer
    (CUKUROVA UNIV, FAC MEDICINE, 2018-01-01) Sedef, Ali Murat; Calikusu, Zuleyha; Bahceci, Aykut; Gokcay, Serkan; Besen, Ali Ayberk; Sumbul, Ahmet Taner
    Purpose: The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lymphocytopenia are markers of poor prognosis in lung cancer patients. The aim of this trial is evaluate the prognostic significance of basal NLR, PLR and lymphocytopenia in patients with extensive stage (ES) small cell lung cancer(SCLC). Materials and Methods: This study was designed as a hospital-based retrospective observational case-series study. A total of 117 patients with extensive stage small cell lung cancer have been treated at four different oncology centers in Turkey between 2011 and 2017. Laboratory results and demographic data were collected. Results: The median follow-up time was 12 months and 95 (81\%) patients died. Progression-free survival (PFS) and overall survival (OS) were estimated, respectively, as 8 and 13 months. 65 (55.6 \%) patients had complete response at the end of first line platin-etoposide combination treatment. The cut-off value for NLR and PLR were determined for whole group and patients were dichotomized into high (>= 3.28) and low (<3.28) NLR groups and high (>= 139.8) and low (< 139.8) PLR groups.. Median OS was lower in patients who had high neutrophil lymphocyte ratio (NLR) (14 versus 12 months respectively). Conclusion: This study showed that basal NLR may have prognostic biological value in patients with ES SCLC treated with cisplatin + etoposide.
  • Thumbnail Image
    Item
    Sunlight may increase the FDG uptake value in primary tumors of patients with non-small cell lung cancer
    (SPANDIDOS PUBL LTD, 2013-01-01) Mutlu, Hasan; Buyukcelik, Abdullah; Kaya, Eser; Kibar, Mustafa; Seyrek, Ertugrul; Yavuz, Sinan; Calikusu, Zuleyha
    Currently, positron emission tomography with computerized tomography (PET-CT) is the most sensitive technique for detecting extracranial metastases in non-small cell lung cancer (NSCLC). It has been reported that there is a correlation between the maximal standardized uptake value (SUVmax) of primary tumors and prognosis in patients with NSCLC. The effect of sunlight exposure on PET-CT SUVmax value is not known. Therefore, we aimed to evaluate the effect of sunlight exposure on PET-CT SUVmax a value in patients with NSCLC. A total of 290 patients with NSCLC from two different regions of Turkey (Kayseri, n=168 and Adana, n=122) that have different climate and sunlight exposure intensity, were included in the study. Age, gender, histology of cancer, cancer stage, smoking status, comorbidity and SUVmax of the primary tumor area at the time of staging were evaluated as prognostic factors. In the multivariate analysis, we detected that the region was the only independent factor affecting SUVmax (P=0.019). We identified that warmer climate and more sunlight exposure significantly increases the SUVmax value of the primary tumor area in patients with NSCLC. Further studies are warranted to clarify the issue.
  • Thumbnail Image
    Item
    Investigation of effects of PALB2 genetic variations on breast cancer predisposition
    (CUKUROVA UNIV, FAC MEDICINE, 2020-01-01) Bilen, Muge Yuksel; Berkoz, Mehmet; Yalin, Ali Erdinc; Calikusu, Zuleyha; Eroglu, Pelin; Comelekoglu, Ulku; Yalin, Serap
    Purpose: In this study, the effects of three different single nucleotide polymorphisms (rs249954, rs249935, and rs16940342) of partner and localizer of breast cancer gene 2 (PALB2) on breast cancer predisposition have been investigated. Materials and Methods: For this purpose, 150 patients diagnosed to have breast cancer and 150 healthy individuals have been included. By using real time polymerase chain reaction (PCR) method isolated deoxyribonucleic acid (DNA) from each case has been investigated for the PALB2 genetic variations. Results: The distribution of homozygote wild type (AA) and heterozygote (AG) genotypes at rs16940342 polymorphism has been observed to be 44.7\% and 55.3\% in breast cancer group and 32.7\% and 67.3\% in control group. The homozygote polymorphic (GG) genotype was not observed in both groups. The discrepancy between the groups in terms of genotype distribution regarding rs16940342 polymorphism has been found statistically significant. However, there was no significant difference in the frequencies of rs249954 and rs249935 polymorphisms comparing both groups. Conclusion: These results show that rs16940342 polymorphism may be an important determinant in terms of breast cancer predisposition in the Turkish population.
  • Thumbnail Image
    Item
    Correlation between 18F-FDG Positron-Emission Tomography 18F-FDG Uptake Levels at Diagnosis and Histopathologic and Immunohistochemical Factors in Patients with Breast Cancer
    (AVES, 2016-01-01) Ugurluer, Gamze; Yavuz, Sinan; Calikusu, Zuleyha; Seyrek, Ertugrul; Kibar, Mustafa; Serin, Meltem; Ersoz, Canan; Demircan, Orhan
    Objective: In this study, we aimed to determine the correlation between pretreatment-staging 18F-FDG total body positron-emission tomography/computed tomography (PET/CT) maximum standardized uptake value (SUVmax) levels and histopathologic and immunohistochemical predictive and prognostic factors in patients with breast cancer. Materials and Methods: One hundred thirty-nine women with breast cancer who were treated between 2009 and 2015 at our hospital and who had pretreatment-staging PET/CT were included in the study. SUVmax levels and histopathologic and immunohistochemical results were compared. Results: The median age was 48 years (range, 29-79 years). The mean tumor diameter was 33.4 mm (range, 7-120 mm). The histology was invasive ductal carcinoma in 80.6\% of the patients. In the univariate analysis, SUVmax levels were significantly higher in patients with invasive ductal carcinoma
  • Thumbnail Image
    Item
    Concurrent chemoradiotherapy with weekly carboplatin and paclitaxel may be a feasible option in inoperable stage III non-small cell lung cancer: a single center experience
    (CUKUROVA UNIV, FAC MEDICINE, 2019-01-01) Calikusu, Zuleyha; Sedef, Ali Murat; Saltaoglu, Pinar
    Purpose: Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). An optimal chemotherapy regimen with concurrent thoracic radiotherapy is not known. In this study, we investigated the efficacy and toxicity of CCRT with carboplatin {[}area under curve (AUC) 2] and paclitaxel (80 mg/m(2)) during CCRT. Materials and Methods: We performed a retrospective survival analysis using medical records of 40 patients with inoperable stage III NSCLC that were treated with concurrent chemoradiotherapy with carboplatin-paclitaxel (AUC 2, 60 mg/m2). Results: The most common histopathology was adenocarcinoma, which was diagnosed in 18 patients (45\%). There were 12 stage IIIA patients (30\%) and 28 stage IIIB patients (70\%). The median follow-up time was 22.5 months {[}95\% confidence interval (CI), 2.9-72.2]. Median disease-free survival (DFS) and overall survival (OS) were 22.5 months (95\% CI, 18.1-27.0) and 53.5 months (95\% CI, 23.5-82.8). Grade 3-4 hematological and non-hematological toxicities were seen in 8 (20\%) and 5 (12.5\%) patients, respectively. Conclusion: This study showed that CCRT with weekly carboplatin-paclitaxel provides similar outcomes to cases in the literature and the regimen seems to be feasible with a low rate of grade 3-4 toxicity during CCRT of non operable stage III NSCLC. Keywords: Carboplatin, non-small cell lung cancer, chemoradiotherapy, paclitaxel
  • Thumbnail Image
    Item
    Silicone implant induced lymphadenopathy after breast reconstructive surgery
    (CUKUROVA UNIV, FAC MEDICINE, 2019-01-01) Calikusu, Zuleyha; Demircan, Orhan; Saltaoglu, Pinar; Ozcan, Nazli